NTRA - Earnings call 3 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Thank you for standing by, and welcome to the Natera, Inc. Q3 Earnings Conference Call. [Operator Instructions] As a reminder, today's call is being recorded. I will now hand today's call over to Michael Brophy, Chief Financial Officer. Please go ahead, sir.

Mike Brophy

Thanks, operator. afternoon. Good joining quarter to XXXX. for of the conference third our our you discuss call results Thank

Diagnostics; webcast. Manager On for be Steve Officer. is Solomon being Clinical also Chapman, is line, John Q&A. Today's our [indiscernible], the I Chief live call broadcast CEO; conference Moshkevich, am Fesko, President on President call Business Chief the Oncology available and of joined and by and via Medical General Officer, of will and

presentation slide be that been will IR be a We the available. Starting also to A investor.natera.com. will site it's of posted has replay Slide as referring potent our X. on as call soon to

and other from may or X-K the materially XX-K, could to Form to statements. the in time that for as filed course future with best strategies finance outlook operationg our forward-looking During important such coverage today's this the product factors for on factors we call, or currently our with and the release Please expected and and successive the time to to most statements risks and opportunities projections, statements of materially. and on documents studies, our our XX-Q to judgment events financial current effects will Form actual our expectations events outlook, including clinical anticipated products, known results recent documents you and contained that regarding capabilities, talk release. Those our to we related our partnerships, based from actual assumptions differ market size, reimbursement make press such cause operational future the base those and differ refer that reflect various and conference and us file results performance including forward-looking results. We SEC, identify future and

contain may during presented If statements. being after the to call or obligation forward-looking call the today, statements [indiscernible] information. XXXX. information today, Forward-looking or the during X, accurate or current this made any replayed call not are update of November any as is reviewed revise made

on guidance or updates but provide do not in unless will during call, we provide guidance so will form. We today's a on performance quarter public the our any further

or performance Steve? will unless we of as otherwise now numeric noted, a and number our represents a comparison. And financial changes each discuss growth over I'd call turn to We Steve. to reference quote year-on-year the like

Steve Chapman

Mike. Thanks,

think strategy the were generated across last versus results year. we're and We off, year-on-year XX% the again I in recovery to absolute QX growth ever volume up our in exceed With our of demonstrate women's ] quarter total I'm product million stronger share year Volumes for the was a $XXX and business. growth, health the paying were excited internal and in revenue the highlights. this QX [ panel. revenues unit health. Signature second [indiscernible] nice and best particularly sequential in growth continues quarter last and versus to of forecast the clinical organ terms strong

to have think cash flat we last improvements. burn tax XX% was QX, that but we gross metrics quarter. Gross as benefits. compared COGS represents talked think As you'll We and was were are, focused XX% it our effort flagged almost margins to expenses well, most as revenue dramatically to leverage this I as contrast, In it getting reduction ASPs this operating improve organic some quarter. Clearly, about improved. and off based on we grew a XX% closer onetime good by XX% the and quarter in ASP rapidly, are basis normalized quarter margins to the results. effort had had also margins those top margin essentially the while an We line in as we encouraged and recall, on on started pay a noted I'm XX%,

also ASP is we in good are seeing to put ASPs payers. guidance the this that a improve leading far think are quickly in QX call, but quarters. sign Mike this is Our us the improvements in about reimbursed efforts later average across so more more store getting will improve we from a significantly talk strong on the trends for position to in in These our future results annual board. continued to

are in We between $X.XXX new now raising total a year. come to guide revenue and and to in once for the billion billion revenue completely again $X.XXX range the expect

the we to to QX guide think of margins and strong year We are and gross expecting repeatable XX%, top between the the margins tightening are QX. in implies which now are range the gross gross margin end land full XX%

any Finally, we are $XXX seeing position is cash be repay year believe the milestone. need dramatically more that in achieved $XXX reduction strategy The hit million. This order to a leaves momentum quarter versus million are been expected $XXX are working. reduction a more core now cash year, our reducing represents burn to good and guideline in in The in not changes for our burn to tax largely we flow we we than breakeven burn significant even cash XXXX. because confidence do guidance that has to we us next million

at innovation continue We are us and to commercial on revenue strong to stable, maps. a while improving road and rapidly focus very team clinical and we competitive ASPs, levels, are COGS keeping maintain growing reducing though OpEx allowing

we've over example, new in trials, within of go investments indications resulting new past excellent after an now technology to product clinical development, and few years, the investments and businesses. products these pipeline made our core For are into and enhancements

major along MRD-related growth. products in As updates with announce future a result, XXXX, to we empower expect other innovations that new and

trials taken we we on of read investments this in major that some have X will side, point. to years be out which controlled the XXXX, more clinical randomized get have expect addition, In or over to

driving previous I'll significant we the on wins are Last nicely drive several conference. the and Week major growth quickly with of We're path investments revenue very we rapid start top breakeven So positioned we multiyear the moving big a the quarter. potential also an landmark for we study growth so during [indiscernible], and catalysts. On we cash share time. had Jason, while financial near-term think future. flow public Kidney to results, our results doing a proven announced us to which area in a in as believe ASN the study at over with [indiscernible] can has be for nephrology leading that week, our

colon just genetic time for or arena that genetic in X,XXX for disease. the draw chronic is chemo care to within these reported the timepoint this gaining strong area way we evidence rather from adoption a patients of by than hereditary patients like ongoing ultimately data example, people and genetic the we large CRC strong new adjuvant actually MRV treatment of reminder, opportunity. The real spend upon detail within very oncology, think proxy test impact of here. The sponsorship notably provides of and exceeded initial the which Signatera care could Signatera. the XX from it is where Nature XX many opportunity use the study but profile population, turn The and clinical diagnostic now evidence that momentum million testing can significant results our becoming call, And a Renasight kidney be excited Feedback finding leading MRD academic to market surveillance and genetic reliable relapse, we affected also adjuvant in has to well overall we we're identify call testing more pharma cancer, focused significantly patients, is performance the value for the radiologic decision-making. part clinical in later now a which X,XXX is longer CKD. As on was this on months. setting, recurrence. This Renasight and ctDNA is actual a underpenetrated at need key been real-world been good in prospective the ESMO for and and a for data large follow-up for waiting serial drug with cancer believe looked of initial utility an as where excellent prognostic the the as States. of cover Solomon molecular foundation coating at-risk will both nephrologists we note more, these positive a [ United vision consortia. the a we than from study. In Signatera coverage. on the Galaxy implementation I'll see The only save the tiny of with More ] included are patients receive cancer that too we we results PD of significant by from precedents has and lives. transform how driver paper and There's lay presented information the potentially at arm go breast fraction we at which while as Notably, causes of that analysis for don't study. and in with positive in it to represents increased The Medicine for strong to Signatera with and predictive is Separately, by historically clinical see a CIRCULATE comparison. I MRD as key as and insights much think backed the

Phase has already. we opportunity Long Phase and II years single might Natera III been already biggest term, fact, term, multiple MRD this a first-mover underway In where be which several with meaningful for the ongoing and have advantage X trials believe

across little call, early-stage show Organization Cancer, randomized the molecular conducted for on to So breast European Phase and describe XX known a Alex molecular treatment by will EORTC. as This [SREP] of the benefits of later Research in new cancer. Treatment including trial which in countries relapse sites treatment the in describing on otherwise CTDNA seeks study led relapse III the is bit a XXX

and studies at collaboration clinical clinical lung and were treatment strong data also our in to in published neoadjuvant, strengthening helped population. In cancer, test and results Two for covers support launch lung position cancer publicly we've monitoring. conducted the October. very of demonstrated performance also these the Medicare we which in presented announced digital seen patient Foundation our strong These XXXX metastatic FoundationOne performance. with key we immunotherapy broad a the across tracker, We the adjuvant for X alone, partners study in and their Medicine pro leadership

year. focus this a cancers. asset oncologists business is on Tracker Gregson The help described. know, best the strong the a with get where across new of [indiscernible] product about over we some path the to stage care had QX Organ as slide. We areas data. with with you efforts volume the were possible we through launch and see pace of offering We're growth, and some the volumes a very pleased to at return don't to into major with account excited last patients Signatera make personalized given strong in strong on health, stable let's about the growth actionable saw compared from the reduce continued women's many I reimbursement Health, to that, particularly trends As will of of decisions growth ongoing time. In next our In advanced growth. we believe

need base larger type saw earlier a we transplant Organ Both large reimbursement testing of As Women's cents this Beru. now they about created when underserved resolved. a been critical That have the prior coming for year, population customers levels. uncertainty that of Health act some Health recurring in across largely reminder, our to QX, offer. can we represent uncertainty order And and has should for

the trends oncology be call, later cover positive. will in Solomon to the volumes where continue the

can required the I the on grew efforts growth. for operations, for we is revenues large billing product to recorded sure we to which as of on The good left from QX all product XX% adjust operational addition growth onetime year-on-year. payment of year. The slide, next in the actually that in see progress reimbursement side that total redouble and our we decision a chart and We because made understates boost think And see, a our that. to a getting of last revenues, you licensing reimbursement that rate growth get you significant volume page, reimbursement year-on-year our up the navigate service. hurdles can covered revenue On improved our XX% revenues were making November right-hand last

a example, we've Since added appeals a team doing new is we've on new information. identified members made We've denied in and better and engineering investment down systems insurance chasing service when For then, processes. missing significant or opportunities.

very early the way see come still that we're still see at starting financial While results, to go. in it's to through efforts great to these and stages, the a we're there's long

of next the we growth of QX then XX% and that the to see Of growth growth revenue year on XX% as on as course, these you in executed QX year can Gross margin described in both in initiatives slide. improvements to the margins, this benefit last past. we've and dipped

we were a call, margins our time, margin normalized estimated factors. that onetime XX% on by organic. gross the On bit gross we margin the that is gross In organic largely basis. about XX% QX described helped QX, In a to some be

We ASPs have in and in are outperformed expectations NIPT seeing improvements Signatera. and modest carrier the our

of have we these in multiple put have in fully initiatives revenue whose each not products, yet recognized place operational approval. been For effects

So cautiously throughout gains the steady deliver XXXX. the that margins optimistic we're we can course gross in

and quarters, in byproduct gross interesting is that older quarterly to cap election in the burn with compared in margin helped significant cycle cash along our improved growth QX the reduction prior Another noticeably improvement. revenue which drive

cost our got projects and This the nice big of as launch during been of projects, Exton see investment off. that company. will of slate sold full we and area a pay to laboratory many it we on continue of investment to budget, goods has infrastructure Signatera executed them and our be to COGS expect marks our XXXX. R&D a expanded within these lab We've Finally, we've hit across

to regulatory NGS Signatera the provider. and the some company NGF project, card validated on alternative passed platform above with using alternate partnership achieve pharmaceutical an alternative that and addition an validation milestone we've regulatory also with In platform. key in major a a We technology milestones

and a on of we milestones, In in addition, centralized alternative we version regulatory which our launch platform the now NIPT may laboratory. NGS validated past

All who business. deeper next on of that Solomon, breakeven RenaCARE Oncology get track to quarter confidence results a give let on in cash will that, to the factors us are me turn these with flow the over we from year. And dive to it

Solomon?

Solomon Moshkevich

from RenaCARE with with system, Natera leaders management. billion goal with of with the gained XXXX prospective determining real-world Colombia, than be testing Medicare renal as NYU, treatment. XX adults. to with was well in Conference of across U.S. can Society was from topic were personalized related I Annual significant was study in received. similar a the spend other medicine, enrolled in its a Many genetics study. Renasight X CKD X,XXX Nephrology in expressed games. And paper patients CKD doctors and to the insights sites about beginning or impaired ASN Thanks, just new genetic back roughly diagnosis Mayo on were at attain it belief American we can where got the Steve. back and wave weekend XX personalized a There that Yale, is nephrology where in people in impressive. feels disease-related oncology genetic the from million ago. hot a collaboration the is health $XX the XXX of burden care Philadelphia The years what to product, RenaCARE often More several XX living this in X results launched the Clinic roughly of institutions, leading of where with are to XX the also how

to level, the the PKD, pathing high key headlines, that in when in their positive XX%, thinking of see slide: the studies received X variance as plan. At in Some test X XJ. reclassified cause the cancer tested X% of XX.X%, compare for all Where can yield the positive criteria a know found Out testing of diagnosis become BRCA tension let's testing positive or has and a rate or DNA patients a pathogenic commercial X oncology X that that germline on insurance a like about of risk X received for in We of and between meaning new including likely or the pain classic have cohorts DNA. germline treatment standard X NCCN coverage. genetic reported high was positive, paces and X diagnostic in Medicare in Renasight's of practice. being meet a and it hereditary you and

for utility, coverage. see end, insurance for and MolDx with clinical opportunity to So given we in an Renasights coverage the clinical that significant we've a for of guidelines with To here great exchanging for recently application high submitted potential Renasight. practice we strong standard yield, seen together a nephrology,

forward here patients RenaCARE look X now a the key or strength that study who already the clinical a only to genetic testing patients of the on diagnosis. little we studies. So stories given is bit Its useful X% been not particularly but in deeper findings. their given of the also a have feedback, unfolding X% of diagnosis is in without

as protocols well For CKD a This measurement left punting The and basic gap. background, of rely significant biopsy. diagnostic has on of causes. as approach imaging spectrum vast has underlying current kidney generally

For of attributed cause whether fact, In genetic driven than cystic hypertension, contains trials. when that CKD. Similarly, There that the the the avoid timely drugs more approximately of kidney already biopsies. to meaning also nonspecific, many the patient mask could in gene-specific cases, a true targets may it's in diabetes invasive found clinical those the patient XXX PKDX, have be and on inaccurately market example, are example. by the be testing XX unnecessary that for that we addressing disease or of it PKDX diagnoses disease, to clinical are helped CKD with management an subtype may comorbidity or now case disease,

options, diagnostic having improve So a information and can can treatment open enhance for they specific really outcome. can ultimately, it in trials participation doors targeted clinical

in want useful paper demonstrating about provides on learn to majority product PKD study vast future testing the diagnoses good that clinicians enable presenting in we website. In pence to evidence who to an standard or diagnosis it solid is and more, tailor and appropriate accurate refine just more We're very of this can of of treatment with of and RenaCARE white people the help CKD. existing to patients same our the For millions published can decisions. an with people lead summary, enthusiastic care a frequently earlier it Renasight and practices that

significant to growth. ordered oncology quarters This had left-hand growth where signature pharma existing quarter. best volumes Signatera all date volumes shown had absolute of physicians units. We patient by never reflects now, The of in clinical quarter. Clinical oncologists initiation, to over increase of new all Moving XX% we perial U.S. the ordered the by includes believe who patients on a X a new testing continued had its Signatera chart right, in and great before. and adoption strong in terms

reminder, a units in August. in in had discussed we which a pharma As [indiscernible], our site call in we

So projects we time broke This a expectations. In a X,XXX. across capacity and coverage XXXs. was to now we've business, continues the and as also pharma which map in types, out bit payers. near-term the cancer QX, ASP significant interest steady that of clinical operational real-world RUO more but among expanded to in expected. better price, execution various XXXs well, it In the see retrospective separately in being coverage some Back as average now we driven by was our road big anticipated to outpacing relative this lumpy improvement above clinical is including indications Signatera, in getting drive continued and such sales We path new Medicare QX, well studies. the as recently closed volumes our is There pharma is the we are expanding data be prospective, labs. to doing private initial

lab is growth studies and or long status, and reminder, labs help term. which in volume Signatera replicate. that the ongoing hard its the near for advanced ADL, the We we've unique drive underway As is all data economic other with will a MRD over very diagnostic announcing to been a believe position

to look studies. that, Alex turn some provide those with to of me let closer at a Alex? over So it

Alexey Aleshin

MRD-positive recently and XX-month support to while the cohort treatment, conference. Thank you, We CRC how data at strengthen not. Seneca from hypotheses continues The Galaxy our MRD-negative updated this data X XXXX patients Solomon. benefit implications presented managed, is year's ESMO have patients do namely, from that the change to

without CPA page, DFS negative side treatment. No were significant randomized to CK vestinal this ACT tablet On differences early-stage care patients show the months regardless in study, We at to believe standard adjuvant receiving negative further definitive the of ACT. of dereslkomahar compared XX survival continue patients in a as of those which CRC. disease-free right-hand seeks strategy Vega the data for de-escalation observed to

this in and treated pathway standard ADP for who top study can assess On we patients will disaPAS-XXX the which page, for DSS tested Altera, after observations. CPAs as believe in chemo is adjusting to that readout it randomized confounding of establish all if the further Signatera. the would significantly This scheduled prive patients MRD-positive the improve have left-hand new possible patients. We see care convictions. intent effect known [indiscernible] of of further trial, improved side with whether compared mid-XXXX, DFS a undergo the of The positive a even treated on the positive, or with with arm

who new this key page on positive based a the and to the enrollment negative, space immediately setting protocol As a XX-month delta decision-making first recurrence. The term the that This molecular is MRD what points focused up we patients on in been reflects X but based majority single reminder, The or the X weeks surgery. are concept study of have outcomes and post is treatment today surveillance on data additive on in in calling surgery. then data on within points, trials time initially surgery. MRD component post in segmentary is and X of time were allows the pose a

a camper Premion orders second to waiting recurrence treatment surveillance as clinical or recurrence. In is on defined detected setting, be positive avert we for in relapse molecular before revolutionize the this a the multiple space market of larger stand. However, on CCDA largest believe treatment and of is by providing based magnitude potentially status initiating radiologic patients instead

companies. primary have and The study studies over collaborate we run III listed this in and recognize now opportunity clinic breast done multiple being this a this In delay and the seen recently of surveillance stage occurrence study whether The patients interest Phase current to study monotherapy in Signatera study delay patent endocrine or The with objective distance that trial new of or including below. I setting. in the metastases and across to recommendation create to have tectDNA the X,XXX approximately expected We design to years if award want take breast HERX with taken in years more XXX highlight positive monitoring results tremendous we And strategy and announced ERP study oral that is and/or with than rolling is third X and from in prevent sites. pharmaceutical successful, the is cancer for Menararini's terial cancer ones ago, broad evaluate patents. early positive space, death. could Signatera the of consortium. the are negative

are Additionally, frame. out be the LEADER interest reading see the to bar molecular breast cancer time recurrence also and and in examining strong They could to we in in XXXX studies. patients on treatment XXXX continue

we ad to lung continue and presentations generate XXXX, highlight and reimbursement generated to support metastatic Signatera treatment cell of have radiotherapy new data and In We neoadjuvant, public clinical cancer. multiple to response immunotherapy the [indiscernible]. events list patents we an want non-coal including and expanding in indications. Today, settings,

from being stages late-stage cancer primarily disease. lung immunotherapy falcell have We in seen utilized to of earlier transition

was multiple final We pretreatment study key that to of recently study XXX median very and across XX% utility, detection lead metric trials strength has Levo set metrics. eligible well of competitors where the lung during for strong performance further state given critical X In in setting, monitoring. In Broad With call. across and active excluding strategy led sensitivity a adjuvant minded XXX% data time. of an observed to establishing This of in XX% perioperative to plan pace. generation IO indications and previously treatment in We X is our clinical studies, the clinical resulted first [indiscernible] are recurrence. to with. maintaining cancer. The and these lung updates approaching setting. being on struggled eater we the reimbursement exceptionality strength published the of believe AVO to neoadjuvant, the of existing a interest recurrence Avidan performance like exceed various data, launched. expense all surveillance with prospective our significant cancer data now approval in a sets have a positioned and cell a reimbursement in with XXX% a the recent I-O presented This longitudinal the patients. Setting so market Signatera to the continue data days key bill a emerging going the has provide We Signatera leadership trials data non-fault the prospective sensitivity to in many

for may with want information a we we in will core recently expanding comprehensive personalized access genomic available or the it test coverage the the to limited IMPower-XXX that POWERX highlight strength announced when product This be are X previously win Fontan Foundation in assay the or icas either exhausted. genomic great derived our with given utilized cracker product like partners are believe was this of efforts the to from exclusively Lastly, studies. Building now with design greater enable ctDNA this on for and to and where Edison, innovative generation data Signatera Medicare monitoring, both analysis combination U.S. IO EM evidence now we and the excited highlight patients, assay We technology FoundAXn-XCDX combines is Natera. across impair that a product is the tracker from profiling this the

excited of data excited PPD clinical for clinical the monitoring the the support present monitoring informed routine integrated our and additional of are to for practice. into to partnership additive business core We effect value

Mike? over review detail. Mike handing financial our Now to to it

Mike Brophy

Thanks, Alex.

revenues results fact year substantially Steve up again had standard can that last see we mentioned. our just that in as versus is slide QX, first slide. despite we a the licensing were The quarter very large

a our that sequential gives flat revenue how now in next sustainable. Operating year growth strong quarters, over The delivered capital and last this some half. though highlights QX very cash really slide the versus effectively even also has for raise last we've growth. the a the and in But highlights that significantly year. we the position. The been expenses revenue some burn balance are the we've seen from faster gross equity product growth last So includes dynamics margins year, strong been September, proceeds in confidence as year remain in modest we me

$XXX You burn as we down the needed stepped we roughly volumes roughly burning of reimbursement put can see up QX. in $XX million rapidly. $XX a on to we've a were all And million set $XXX quarter infrastructure that in burn Signatera. grew now million half average to in XXXX a to quarter in deliver first-class launch and at We as here to million

recently in the innings still to XXs. stand a the standard of QX. sales projects QX. burn early here some As in fully topic getting reimbursement of I'll dramatically outstanding fell we are for given we on be on in you'll have getting emphasis and quarter the offer planned Steve we in the quarter-to-quarter results we services. all are our some Days think that lot do while caveats track, placed now COGS described, effort, covered cash We fluctuate do and than here. expect in large low we And

next However, we see I car that more in continued you Great. to and progress, dinette of here year. think the trend the expect see

the to guide the page. get XXXX on Let's next

in the once are and again revenue a to guide we expect come to to upwards described, position in $X.XXX billion Steve $X.XXX at billion. As completely now rerate

the to tightening that $XXX into our the guide expect expected be guide it to And cannot year million. we pleased to the burn million is range. $XXX since unchanged, the for margin remaining drop be reduce guide OpEx now original are cash and We gross means significantly

Obviously, followed have to growth which we but good what timing some the guide try set that and requires practice. for margins, this ASP in around are that And I continued we imply does the achievable why specific continue forecast of however, ASP you obtained per know not guide grow that's ASP. that but time, that of us we are upside clean making uncertainty many We've execution. focused This that got guide implies. you'll year. happen, reserving there's to to to usual improvements, think on some always our this For the is improvement, they we as

and rep team counts function feeling XXXX, continue we've growth, are rep remaining sales As feel Steve we about are year. largely positive a described, given sales the got are next productivity like stable right-sized of we very units to and driving

year because same to larger those will achieved team they're at we business the think ultimately time of good will a good units. I This repeating a same unit target. growing existing require is commercial this the book our manage as execution growth

starting upside, to revenue at this faster as now increase volume are In pace ASP to we addition a improves. see particular

our further strong forecast. got the So we've for would regard be that if another base number helping as of that political ASP to I could upside [ a tailwinds upside 'XX. us our ] trends revenues, continue, in On factor

announced tax footnote not making broad we We NCCN guidelines. inclusion Based to we ASP are meetings been relatively would which of targets in fit these XXXX we've need the margin steady in [indiscernible] that screening our panel the cautiously and the the I'll on progress continue again it could update course say of support from year. optimistic do early guidelines flow in gross order in breakeven next over improvements on XXXX. on carrier publicly and expect committees, guideline the

expense sold for expenses to trials leverage the operating XXXX. contingent in XXXX Signatera. compared getting make about infrastructure We've we expect rapidly to to We R&D study and talked stable operating are and our still prospective lab team, Holding on us reductions. clinical allow will commercial relatively investments be critical in

We and are leader more to are a those planning we to the compelling future. new about also products, talking looking forward launch in

get in pace without sacrificing breakeven growth goal and is to XXXX overarching to innovation. Our

early significant X it we're X detach. data objective, investment readouts, planning this data of we forward would by still then XXXX. allow next with evaluate was the half criteria, very of only pass-through spend If end or year That that of about program. $XX in and the either and on early those strong will Given the first deliver us moving the QX million other come cancer will to in to year investment very

flow the goals. results products, think we're we will have goals if front area we and in further see we cash excellent Given the core leading, of hitting can we us only put market future into our in this in our that be

Operator? to with talking about me really to we're of open the excited be it future let Natera up that, and Q&A. So

Operator

Instructions] with Tejas Morgan line first from the your of is [Operator Stanley. question Savant

Tejas Savant

gross gross like Congrats year Mike, quarter pointing either comments quick you for Can benefit or on It contextualize have really light the revenue of as on fourth just help math. of just and onetimers flattish well you're flattish in margin. in didn't that a to from you my looks your that any quarter margins guidance. us great quarter. implied sort sequentially growth Steve,

any color on offsets of typical the year-end sort versus any So that should we think seasonality.

Mike Brophy

range Thanks to end think top better of for gross Yes, the tightening look, implies in that the margins, similar on gross I the just on or question. think the It's margins I Mike QX. here. that's guide,

know, kind know, As don't specifically as guys to you of you guide we quarters.

of that should I of kind a there. as taken concerns underlying about trends. a level message be there's caution about don't So think

of sentiments As QX really is remain our are the seasonality good is but the a quarter strongest a of typically trends echo QX QX well. women's in business. kind you've line. this the follow also that across of where from health pattern terms heard quarters business incredibly underlying on quarter, and Volumes our usually, the is the revenue similar -- strong. I the weaker prepared QX remarks, in kind as

we're good we with. to start felt off So a

hope in As of be good guidance, provide to to of providing kind and is I achievable our we for my remarks, I benchmarks financial mean kind this. able try to to always mentioned approach exceed but to prepared guidance

Steve Chapman

ASPs is QX, an volumes. acceleration say, Steve. think, Yes. off would see, I'll in just add. to, continuing start strong we're We're to This in and in I incredibly I and

Tejas Savant

part we've California, being of that And here. how is X update a couple the then material I super a bill on just your us biomarker Signatera. helpful of of the Can And do investors a gotten well. color. That's Got know in opportunity in your with on the FX up status juxtapose sort passed you coming it. but as terms And that follow-up, question this BSA. got you've tracker it's from with you guys, revenue,

actually color my then of on on follow-up the part that? any second Renasight. And is So

really the XXX,XXX I in curve? of mentioned you think slope thinking that adoption strong you but the diagnosed Given annually. about -- population, mentioned patient How million XX about about newly results the RenaCARE. the in are here past, Steve, had you

from in be feedback payers would the of and So slope uptake fantastic. early just nephrologists the there and any of terms

Steve Chapman

Yes.

little bit I biomarker states. commercial quite more of a paste But through. reality a that in groups actually how I of very the the the in now the biomarker payers a obviously come cautious sort critical We're a monitoring bit number guess, builds bill, We're of approach. are talked that. and So just other We taking see want to think have some and first, significant place on have about is things. of presented things

California positive. And think to as pace the we So it see Shield not bill been quicken overall, Blue that with for commercial But net would an for that's unique that sort an coverage. serve I traditional passing, It's things previously. is California. a think, of of could opportunity is period available that's its biomarker something opportunity resolved with obviously, I this say time that you and

-- stage interest XX% RenaCARE they like So a -- to from frankly, nephrologists we have like being this very done experienced thousands something product the I the study, nephrologists tens versus before, this. mean might starving the community it's already Renasight like end the From engaged said the get of standpoint, welcoming previously nephrology been we've where product really is We've I excitement product up of this incredible. this we've haven't of and tests seen with a is historically. think it's at real point. in think, and path the the arms. They're a inflection about used are coverage quickest what I that they've for open commercial

said, new, I penetration about size, comparison here impactful. be is take cancer incredibly a market a a So while When hereditary market get to excited cancer opportunity. where protocols of you any type testing. can they're that introducing with There, be think large place incident a size. today situation the think pools. about the that. have something I similar With get in you testing does that time it and very and hereditary that we're you're of have very prevalent sort made similar frankly, direct an And And could

the laying we're something think groundwork for we so similar. And

Operator

line next of question with Leerink Puneet the Your is Souda Partners. from

Puneet Souda

could ADLT you're potentially -- guidelines follow-up seeing then And mean, and indication and I -- well on improvement. have, I appreciate giving that So of with the ceiling side? good commercial a the have improvement And outline talk first Signatera, I then you there guideline Panorama X details payers. on ASP, see help you what's sort much reimbursement, and and the expect could what about on ahead -- should how you what given rate Horizon the inclusion the ASP, on we you expansions was on which But could to on it's Signatera. here ASP the as the the

So about maybe just talk ASP.

Mike Brophy

the Thanks, question. Puneet. I appreciate

continued So covered. first pretty addition on we in we Signatera yes, the in the improvement ASPs, ASPs, rapid saw to which

We ASPs. carrier also I women's and that's think Panorama and very for in health improvement screening. for the saw some encouraging mean both I

look, And the of kind we year, I erosion point. category. actually but guided And of haven't the erosion. frankly, seen it's ASPs recall actually we more seen in may earlier some time, seen we've it's that we've a at seeing assuming in that said, improvement. You the [indiscernible] in indeed, some And it not that because we're some

and comes of from? It covered sources, improvement we've variety really Now a small it's and last that some Steve really detail the where the call. we've that from does range of in the making efforts year, on from been been contributions come over a

very the about the So leading actually I on think aside, right ASPs, which of the women's rapid signatory ASPs which be could health, to encouraged did seen in we're that improvement the I'm trajectory guidelines have I seeing we've quite we in nothing expect. now say impactful,

follow-up again again, you remind just me you give a just can X time. question, more Second

Puneet Souda

Yes.

ceiling the about indication that with expansions? think is the and Signatera ADLT what how for you Just

Mike Brophy

yes. Yes,

for typically and just covered grinding hurdles $X,XXX, space. and blocking in sure administrative through we clear and this encounters kind get dynamics And that of now, we a like So right that feel path we're just on making current I there's covered we think on the myriad tumor all based prepared beyond tackling just what seeing of Solomon the kind coverage our it remarks the have in that types, services. paid current on of that we X

I also So we're at we I levels, lot the NCCN se. think we'll I different wouldn't from then biomarker room sources. that a randomized data. that's and have feedback per that have touched now. also run more time in the to data, are to data have number going have We're of a Steve reaching where ceiling to a on from mean, on we're of prospective put about those legislation. going we'll

hit going to So some there's that are roughly catalysts other contemporaneously. other potential

which is So I areas smooth trajectory of encouraging. say really the to a would piece, kind expect fairly

Steve Chapman

I'll just Yes. add too.

and is, I now this growth revenue things cash breakeven looking to 'XX think X strong very flow very of we're in ahead that as changes, clear incorporating at a any exciting path like the really just the upside we're really things or opportunity about minute was biomarker asked guideline from of a not upside from of the ago. that any legislation, which opportunity is

upside are looking really don't and improvements, we're all good includes that upside, status but blocking those just and and potentially that at have to need things to year. model really very the we operations another get of quo billing significant So cash breakeven sort tackling other just flow of and

Puneet Souda

sure like? Altair that the maybe and the when on or data Signatera if NCCN Could number can translate And the Solomon -- say this Alex wondering you coming that that correctly. NCCN B inclusion, that. on elaborate maybe health side, treat given side, If does is you -- inclusion did have That then on what then for to guidelines, of to just up. And with guideline maybe you sets could guideline elaborate question in look already guess and you guideline A heard ctDNA clarify see could Got the I wasn't can expecting question. this XX you're XXXX. on you Mike, a very women's Q it. early helpful. the I update part I into

Steve Chapman

Yes.

about health. First, women's let me just talk

we course, of committee was we on a So there forth. that happened know guideline don't do what any meeting. information and But have exactly so

from about be expanded SMART could the screening. I just think behind think or things really are either see be in you about that the feel way. know don't results in of behind ACOG. I positive Whether in think fundamentals if start from outlined September, strong QX. carrier the XX you to study We and that negative, of that, will line sort we fundamentals but time the that testing And Q the might

from side From a NCCN there look was of at kind So have year. in kind what August, to that stay outcome. tuned submitted meeting outcome was the there. or year see to you course, of was when know next maybe know this early it an included XX-month things, later the we review just think We time. circulate -- we're because data hear the the we'll the of happens in do But I that don't and expecting in of

great the results have will from on the out. escalation Altera example, XXXX, for in Now we X initial actually working ago. In setting, years reading randomized Natera thing we results because started care, than controlled the is trials for all more

respect to what with will committee So year out. this the of results be Circulate says study the Altera next the regardless guideline year,

matter is reads so trial the out setting things. very what and just a look when And at time, that's positive we really why assuming Altera. of feel And about positively, it's you

treated. are treated are are treatment are molecular where components think sort being Altera negative either monitored when not arm randomized positive, they into then flip and with at the they that And CTDA. screen over time. study the from that then and One or on treatment a is recurrence I settings. patients other X it escalation. Vega But has is of initially the

So why which is reason molecular I testing as important. we're think another treatment surveillance is we excited well, about think, recurrence readout that on

to So add read else? anything out. like to you Alex, Solomon, having of look would forward both those

Operator

line Baird. Catherine Schulte question the with is from of next Your

Catherine Ramsey

quarter. I like a to that of give that new products MRD Could you liquid are a the some details for mentioned version? on launch on the I kind platform Steve, indications? off-the-shelf referencing any Congrats you planning additional first, or additional think you exome be Will next more Or guess, potential tumor-naive year. new

Steve Chapman

Yes.

investing as development out, new in research heavily business. So across been MRD, have to history we're coming innovation things the are but number particularly not that's and we that we've year. the multiple entire really updates in And I of think just going and to years. over start product but next and fruit have launches bear company, the of significant the going And now last a to of couple

the So hear MRD side, multiple opportunities, updates. I different products to would expect on new and product both

Catherine Ramsey

Okay. your the additional sequence in over. volumes can color all out then the an Signatera NGS And [indiscernible] your on to you What's there? rolling Great. validating give is central NIPT switch and to mentioned line plan you And time alternative Any provider. alternative here the of lab?

Steve Chapman

Yes.

market bit on the sequencing. and the quite different guys I there. out different know think several we've groups So done open many instruments, years, over last there's really, of of of evolution and the seen up the we history now you work multiple we've think sort here And a

to partners great NIPT that and best service validate getting flow breakeven able and now the the platforms. reducing we're to cash our and we alternative regulatory decision We're Natera collaboration on on independently we've these been and COGS So milestones validate so it's Signatera pharma level, on focusing the quality. price and make meet with on to in based for going what the provider use

Operator

JPMorgan. Your next Rachel with question is from of the Vatnsdal line

Rachel Vatnsdal Olson

Congrats the you on quarter guys.

meaningful Foundation size we in here. So off, One that how contributor can become walk should just see Can opportunity? nice through the coverage last the kind And us you to quickly of then month. U.S. tracker a of how the it first

Mark Massaro

take don't that? Yes, you Solomon, why

Solomon Moshkevich

tests. given immunotherapy tissue and and might for excited sample the great thought the Signatera, FoundationOne Tracker support first exhausted send to we patients is analysis tissue Sure. profiling. another were cancer and for FoundationOne where already Medicare very test patients advanced without already scarce appropriate the setting who that's positioned it the for generated data for for CDx already getting you needing very that be genomic Yes, of to to useful question. getting thank monitor are want We well a development the was response coverage in about to after for especially that's been

and So Foundation led rolling that to forward exciting, Medicine being we and out patients. that's by of look lot helping that commercialization a

Rachel Vatnsdal Olson

year. my in then upcoming Rabgen pending just next that you want And to Great. with ask early trial the follow-up, the lawsuits guys in I have about

had million in X other peers settled have court. out the range, of out pay peer have to high You that but $XXX

peer earlier in. X be that is their payout week all range had You this going flagged that $XX in million to like

tissue? walk you any up are color the And what to us for can on just range So that we dates potential leading see outcomes that trial? of could through

Mike Brophy

question. the for Thanks

So updates believe I some are as feel litigations can't very they like kind lot providing don't all patents got we don't defenses. of we litigation, available. a got we just leave that -- we become and of look just we've it ongoing unfortunately, strong valid, And now. infringe. to that's intending the the forward on We we've details to think into clearly But where for more get

Operator

is line with of Brennan Your Cowen. the next question Dan TD from

Daniel Brennan

one, first evaluate year, move later the screening data about some you and only X coming Maybe up would in looks you the and talked talked these year out ahead? here very early to Mike, any to you Can coming just see the next And data order push that's the if in this forward of us and studies? about would give you what results. sense of excellent we level more around of you need a expect evidence strong, color

Steve Chapman

Yes.

take I'll that. is this So Steve.

competition at once going that case-controlled the So we're decision we've cetinoma. trajectory And look. there. coming there's at to early I both how breakeven are we to said impact to anything measure ability looking -- that out cash we cash there. end all we sort points with And up think those a There's maybe we going the in and flow And up we're additional to where before to of of out our advanced in are others study do we're get the X sort to see have probably hand, our that's study year, compare of do to do at financials to an following that's have breakeven. how and going And of not how we January. on this then flow

be forward a whether we're unmeasured environment So move I we we're where think we ball if XXXX, moving do next milestones -- the the different we'll positive. in key really we forward, right where think where and the operating would be in we're waiting approach, before we'll we hit XXXX And not. the the or be decide to in ball phase-gated approach steps cash flow think taking

Daniel Brennan

expect getting I what like you could and Got update maybe then just volume but just to -- bit the if on related are and commercial much regimen early data it. likely current next year, I and that arm obviously, inclusion, impressive. Galaxy as question, kind an does different mean? a then that successful the a footnote start another positive really -- a as maybe you'd benefit be ALTAIR? would a And of that X does NTCN, that guess, know just you maybe think the looked mentioned How in coverage see what MRD the little ALTAIR. derisk you I XX-month might Obviously, clarify

gives much confidence you how wondering readout. in Just positive ALTAIR of that

Steve Chapman

Yes.

have me then and I'll on Alex circular talk comment quickly Let the guidelines, just data. about

really guidelines commercial the we now the reimbursement. -- think commercial and seeing bill, a also you to we're continue. coming going biomarker on growing need pace. So we're fast to to And volume that's reimbursement and why do you right get -- volume at of because grow And now

those grow this breakeven business. cash guidelines Natera, far obviously at So point, pace coming don't think would going continue I quicken And of here without we think guidelines in. for things. to achieve get guidelines importantly, significantly and the really we're need I to flow along But it's to the --

we what if up in wait and the ALTAIR it out, So time coming see -- be we we'll we'll do great have this study and but end a getting happens around, position.

comment whether Circulate you ALTAIR Alex, So on data, the to want that's derisked do Vega.

Alexey Aleshin

Steve. absolutely, Yes,

corner, absolute reverse. ALTAIR We study. in have the difference in derisk Vega definitely actually the arm study. not CTA have of furthermore, in cancer separation if think and active positive approved TAS-XXX, of of health eliminate adding also the is the the continue has none curves seen already we in curves and a not extrapolating second is help is but findings continuation the is have We've are we agent, does designed We around risk of very way way from I to CT that's care any, Altera And XXX% without just we seen study, negative these the And the risk, almost third-line that And even that CIRCULATE we've helps think patients seen are those setting. that. benefit And arm up that colorectal chemotherapy see and positive adjuvant recurrence in we've So both little, that adjuvant actually, seen now the shrunken just chemotherapy. since treatment. known that reduce that to coming efficacy those but the CTA

we study patients by something until design, the is see Again, that pretty there. the the we But findings that positive. we're unblinded. study results we given think so won't the effect study. should if So will far either the data, circular an I able from given is to But the are to very be drug adding to should be from or and that bear that that be get out randomizing know effect get able placebo, confident there

Operator

have back question that hand now closing for of for I presenters lot the our a any conclude does will we remarks. This time to call answers. over and

Mike Brophy

Thanks, for with about operator, excited today. us very everyone pleased we're joining you. share and and these to to really results, We're thanks

again thanks joining. So for

Operator

today's call. Thank concludes This joining. you for

may You now your lines. disconnect

Natera (NTRA) 8 Nov 232023 Q3 Earnings call transcript